ipi-926 has been researched along with Medulloblastoma* in 2 studies
2 other study(ies) available for ipi-926 and Medulloblastoma
Article | Year |
---|---|
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.
The Sonic Hedgehog (Shh) pathway drives a subset of medulloblastomas, a malignant neuroectodermal brain cancer, and other cancers. Small-molecule Shh pathway inhibitors have induced tumor regression in mice and patients with medulloblastoma; however, drug resistance rapidly emerges, in some cases via de novo mutation of the drug target. Here we assess the response and resistance mechanisms to the natural product derivative saridegib in an aggressive Shh-driven mouse medulloblastoma model. In this model, saridegib treatment induced tumor reduction and significantly prolonged survival. Furthermore, the effect of saridegib on tumor-initiating capacity was demonstrated by reduced tumor incidence, slower growth, and spontaneous tumor regression that occurred in allografts generated from previously treated autochthonous medulloblastomas compared with those from untreated donors. Saridegib, a known P-glycoprotein (Pgp) substrate, induced Pgp activity in treated tumors, which likely contributed to emergence of drug resistance. Unlike other Smoothened (Smo) inhibitors, the drug resistance was neither mutation-dependent nor Gli2 amplification-dependent, and saridegib was found to be active in cells with the D473H point mutation that rendered them resistant to another Smo inhibitor, GDC-0449. The fivefold increase in lifespan in mice treated with saridegib as a single agent compares favorably with both targeted and cytotoxic therapies. The absence of genetic mutations that confer resistance distinguishes saridegib from other Smo inhibitors. Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Western; Comparative Genomic Hybridization; DNA Primers; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Immunohistochemistry; Kruppel-Like Transcription Factors; Magnetic Resonance Imaging; Medulloblastoma; Mice; Molecular Sequence Data; Pilot Projects; Real-Time Polymerase Chain Reaction; Receptors, G-Protein-Coupled; Sequence Analysis, DNA; Signal Transduction; Smoothened Receptor; Survival Analysis; Veratrum Alkaloids; Zinc Finger Protein Gli2 | 2012 |
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
Recent evidence suggests that blocking aberrant hedgehog pathway signaling may be a promising therapeutic strategy for the treatment of several types of cancer. Cyclopamine, a plant Veratrum alkaloid, is a natural product antagonist of the hedgehog pathway. In a previous report, a seven-membered D-ring semisynthetic analogue of cyclopamine, IPI-269609 (2), was shown to have greater acid stability and better aqueous solubility compared to cyclopamine. Further modifications of the A-ring system generated three series of analogues with improved potency and/or solubility. Lead compounds from each series were characterized in vitro and evaluated in vivo for biological activity and pharmacokinetic properties. These studies led to the discovery of IPI-926 (compound 28), a novel semisynthetic cyclopamine analogue with substantially improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and compound 2. As a result, complete tumor regression was observed in a Hh-dependent medulloblastoma allograft model after daily oral administration of 40 mg/kg of compound 28. Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line; Drug Discovery; Hedgehog Proteins; Humans; Liver; Medulloblastoma; Microsomes; Signal Transduction; Stereoisomerism; Veratrum Alkaloids | 2009 |